Afamelanotide Side Effects: Safety Signals and Warnings
Afamelanotide safety concerns are compound-specific. The main listed side effects are Nausea (most common), Implant site reaction, and Skin darkening. The main warning signals are Regular skin and mole examinations recommended during treatment, Not studied in patients with active melanoma or high melanoma risk, and Liver function should be monitored in EPP patients.
Direct Answer
Afamelanotide (Scenesse) is FDA-approved for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP) - a rare, severely debilitating condition. The Phase 3 evidence in EPP is solid and the approval is well-founded. Outside EPP, evidence for vitiligo is emerging in Phase 2. This is a legitimate, approved therapeutic for its specific indication.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Skin & Beauty
- Best for
- Erythropoietic protoporphyria (EPP) phototoxicity prevention, vitiligo (investigational), melanocortin research
Reported Side Effects
- Nausea (most common)
- Implant site reaction
- Skin darkening
- Headache
- Fatigue
- Darkening of pre-existing nevi
Warnings
- Regular skin and mole examinations recommended during treatment
- Not studied in patients with active melanoma or high melanoma risk
- Liver function should be monitored in EPP patients
- Use only for confirmed EPP diagnosis
Known or Plausible Interactions
- Photosensitizing medications (additive pigmentation changes)
- Anticoagulants (implant procedure may cause bruising)
- Hepatotoxic drugs (EPP patients may have compromised liver function)
Regulatory Context
FDA-approved (Scenesse) for erythropoietic protoporphyria (EPP) in adults. Also approved by EMA. Available only through restricted distribution programs (REMS). Prescription only.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | EPP Phototoxicity Reduction (Level A), Skin Pigmentation (Level A), and Photoprotection (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Afamelanotide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/melanotan-i-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.